GSK Partners with LimmaTech for Further Development of Quadrivalent Shigellosis Vaccine
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity